Periprocedural Bridging Therapy in Patients With Mechanical Heart Valves

Mechanical heart valves (MHVs) are thrombogenic and require lifelong anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Periprocedural bridging with unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) aims to reduce the risk of thromboembolic events in patients. Cur...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 16; no. 3; p. e56465
Main Authors Balaji, Nivedha, Olukayode, Oluwafemi, Faiz, Fardeen, Dixit, Priyadarshini, Bhavsar, Vedang
Format Journal Article
LanguageEnglish
Published United States Cureus Inc 19.03.2024
Cureus
Subjects
Anticoagulants
Blood clots
Cardiac arrhythmia
Cardiology
Heart failure
Hematology
Internal Medicine
Magnetic resonance imaging
Mitral valve stenosis
Patients
Prostheses
Rheumatic fever
Surgery
Thromboembolism
Thrombosis
Ultrasonic imaging
United States > US
bridging anticoagulation
mechanical heart valves
low-molecular-weight heparin
unfractionated heparin
thrombus
Online AccessGet full text

Cover

More Information
Summary:Mechanical heart valves (MHVs) are thrombogenic and require lifelong anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Periprocedural bridging with unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) aims to reduce the risk of thromboembolic events in patients. Currently, there are no definitive class I recommendations for anticoagulation management in patients with MHVs. In this report, we present the case of a 77-year-old female who was perioperatively bridged with enoxaparin and subsequently developed an acute thrombus.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.56465